Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against TG Therapeutics, Inc.

NEW YORK–(BUSINESS WIRE)–Robbins
Geller Rudman & Dowd LLP
(http://www.rgrdlaw.com/cases/tgtherapeutics/)
today announced that a class action has been commenced on behalf of
purchasers of TG Therapeutics, Inc. (NASDAQ: TGTX) common stock during
the period between June 4, 2018 and September 25, 2018 (the “Class
Period”). This action was filed in the Southern District of New York and
is captioned Reinmann v. TG Therapeutics, Inc., et al., No.
18-cv-09104.

The Private Securities Litigation Reform Act of 1995 permits any
investor who purchased TG common stock during the Class Period to seek
appointment as lead plaintiff. A lead plaintiff acts on behalf of all
other class members in directing the litigation. The lead plaintiff can
select a law firm of its choice. An investor’s ability to share in any
potential future recovery is not dependent upon serving as lead
plaintiff. If you wish to serve as lead plaintiff, you must move the
Court no later than 60 days from today. If you wish to discuss this
action or have any questions concerning this notice or your rights or
interests, please contact plaintiff’s counsel, David
A. Rosenfeld
of Robbins Geller at 800/449-4900 or 619/231-1058, or
via e-mail at djr@rgrdlaw.com. You
can view a copy of the complaint as filed at http://www.rgrdlaw.com/cases/tgtherapeutics/.

The complaint charges TG and its Chief Executive Officer with violations
of the Securities Exchange Act of 1934. TG is a developmental
biopharmaceutical company focused on the acquisition, development and
commercialization of novel treatments for B-cell malignancies and
autoimmune diseases. The Company is developing two therapies targeting
hematologic malignancies: TG-1101 (ublituximab), a glycoengineered
monoclonal antibody that targets a unique epitope on the CD20 antigen
found on mature B-lymphocytes, and TGR-1202 (umbralisib), an orally
available PI3K delta inhibitor. During the Class Period, TG was engaged
in a randomized controlled Phase 3 trial to evaluate TG-1101 in
combination with TGR-1202 for patients with front-line and previously
treated Chronic Lymphocytic Leukemia (“CLL”), known as the UNITY-CLL
Trial.

The complaint alleges that during the Class Period, defendants made
false and misleading statements and/or failed to disclose adverse
information regarding TG’s business and prospects. Specifically, the
complaint alleges defendants failed to disclose that TG was involved in
cleaning the data collected in the UNITY-CLL Trial and, as a result, was
able to gain an understanding as to the efficacy of the combination
therapy; that, as a result of that data cleaning, TG knew the UNITY-CLL
Trial had failed to meet its stated goal, and that, as a result, the
Company would not be able to seek accelerated approval; and that, given
that the UNITY-CLL Trial had failed to meet its stated goal, it was
highly unlikely that the combination therapy would meet its primary
endpoint of increased progression free survival – in other words, the
drug therapy had failed. As a result of defendants’ false statements
and/or omissions, the price of TG common stock was artificially inflated
during the Class Period to as high as $14.70 per share.

Then, on September 25, 2018, TG announced that it would not be releasing
the data from the UNITY-CLL Trial and that it had failed to meet the
trial’s stated goal. The Company issued a press release announcing that
the Data Safety Monitoring Board had met to review ongoing data from the
UNITY-CLL Trial and had advised the Company that the interim analysis of
the study data could not be conducted at this time because the data was
not sufficiently mature to conduct the analysis. In response to the news
that the UNITY-CLL Trial had failed to meet its stated goal and that
potential commercialization would be greatly delayed, the price of TG
stock declined 44%, falling from $9.25 per share to $5.15 per share.

Plaintiff seeks to recover damages on behalf of all purchasers of TG
common stock during the Class Period (the “Class”). The plaintiff is
represented by Robbins Geller, which has extensive experience in
prosecuting investor class actions including actions involving financial
fraud.

Robbins Geller is one of the world’s leading law firms representing
investors in securities litigation. With 200 lawyers in 10 offices,
Robbins Geller has obtained many of the largest securities class action
recoveries in history. For five consecutive years, ISS Securities Class
Action Services has ranked the Firm in its annual SCAS Top 50 Report as
one of the top law firms in both amount recovered for shareholders and
total number of class action settlements. Robbins Geller attorneys have
helped shape the securities laws and recovered tens of billions of
dollars on behalf of aggrieved victims. Beyond securing financial
recoveries for defrauded investors, Robbins Geller also specializes in
implementing corporate governance reforms, helping to improve the
financial markets for investors worldwide. Please visit http://www.rgrdlaw.com
for more information.

https://www.linkedin.com/company/rgrdlaw
https://twitter.com/rgrdlaw
https://www.facebook.com/rgrdlaw
https://plus.google.com/+Rgrdlaw/posts

Contacts

Robbins Geller Rudman & Dowd LLP
David A. Rosenfeld,
800-449-4900
djr@rgrdlaw.com

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.coom for scheduling information.